[Skip to Content]
[Skip to Content Landing]
Citations 0
April 27, 2005

Arthritis Medications and Cardiovascular Events

JAMA. 2005;293(16):1975-1977. doi:10.1001/jama.293.16.1976-b

To the Editor: I would like to add a cautionary comment to Dr Topol’s Editorial discussing the apparent prothrombotic hazard of COX-2 inhibitors.1 The excess number of thrombotic events with rofecoxib and celecoxib in the trials assessing their ability to inhibit the development of colonic adenomas is potentially a confounding effect generated by their analgesic properties.

First Page Preview View Large
First page PDF preview
First page PDF preview